DrugPatentWatch Database Preview
Nabriva Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for NABRIVA, and when can generic versions of NABRIVA drugs launch?
NABRIVA has two approved drugs.
There are four US patents protecting NABRIVA drugs.
There are one hundred and one patent family members on NABRIVA drugs in thirty-nine countries.
Summary for Nabriva
| International Patents: | 101 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Nabriva
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nabriva | XENLETA | lefamulin acetate | SOLUTION;INTRAVENOUS | 211673-001 | Aug 19, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Nabriva | XENLETA | lefamulin acetate | SOLUTION;INTRAVENOUS | 211673-001 | Aug 19, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Nabriva | XENLETA | lefamulin acetate | TABLET;ORAL | 211672-001 | Aug 19, 2019 | RX | Yes | Yes | 8,071,643 | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nabriva Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3299356 | Start Trial |
| China | 103080083 | Start Trial |
| Brazil | 0112452 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
